clinical trial · NCT06388902
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
BioRay Pharmaceutical Co., Ltd.·phase1·suspended·n = 120
Advanced Solid MalignanciesBR115 for injection
brief summary
This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR115 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BR115 for injection in patients with advanced solid malignancies. Patients will receive two doses at the first week of treatment, followed by once per week until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation, or withdrawal from the study.
started
Feb 19, 2024
primary completion
Aug 1, 2028
completion
Dec 1, 2028
last updated
Nov 21, 2025
official title
A Phase I Clinical Study of the Safety, Tolerability and Efficacy of BR115 for Injection in Patients With Advanced Solid Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol